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Abstract
Background: Early detection of loco-regional breast cancer recurrence improves patients’ overall survival, as treatment
can be initiated or active treatment can be changed. If a suspicious lymph node is diagnosed during a follow-up exam,
surgical excision is often performed. The aim of this study was to evaluate the diagnostic performance of the minor
invasive ultrasound-guided fine-needle aspiration cytology (FNAC) in sonomorphologically suspicious lymph nodes in
breast cancer follow-up.
Methods: Between April 2010 and November 2012, we performed ultrasound-guided FNAC in 38 sonographically
suspicious lymph nodes of 37 breast cancer follow-up patients. Cytological specimens were evaluated if the sample
material was sufficient for diagnosis and if they contained cancer cells. Patients with negative cytology were followed
up clinically and sonographically. To evaluate the diagnostic performance we calculated sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV) for physical examination, the different sonomorphological
malignancy criteria and FNAC.
Results: In 36/38 (94.7 %) lymph nodes, the pathologist had enough material to establish a final diagnosis; in 2/38 (5.3 %)
lymph nodes, the probe material was non-evaluable during cytology, these 2 were excluded from further statistical
evaluation. Cytology revealed malignancy in 21 lymph nodes and showed no evidence for malignancy in 15 lymph
nodes. There was no evidence for malignant disease in follow-up exams in the 15 cytologically benign lymph nodes
with an average follow-up time of 3 years. The diagnostic performances of physical examination and FNAC were:
Sensitivity 52/100 %, specificity 88/100 %, PPV 85/100 %, NPV 60/100 %, respectively.
Conclusions: Our preliminary results show that FNAC is a safe and fast diagnostic approach for the evaluation of
suspicious lymph nodes in the follow-up of patients with breast cancer and, thus, together with follow-up represents a
feasible alternative to surgery.
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Background
Breast cancer is the most frequently diagnosed solid can-
cer in women and one of the leading causes of cancer
deaths in the western world [1]. While screening mam-
mography has led to the earlier detection of breast can-
cer [2], and guideline adherent therapy has improved
overall and recurrence-free survival [3], detection of
breast cancer recurrence remains difficult [4]. Data from
meta-analysis and retrospective studies confirm that
early detection of local recurrences resulted in signifi-
cantly better survival as compared to late detected recur-
rences [5–7].
Regional lymph node recurrence is uncommon and
has been reported in 1–3 % of patients with early stage
breast cancer and in 1.7–15.9 % of patients with any
stage of breast cancer [8]. The examinations performed
to detect and assess lymph node recurrence should be
reasonable regarding the patient’s quality of life and
time and cost-effectiveness [9]. Follow-up exams have
to manage the difficult task of not inducing too much
anxiety in patient with unnecessary exams or interven-
tions and to minimize complications and costs [10].
Loco-regional recurrence includes recurrent disease in
the diseased breast and the ipsilateral lymph nodes in
the axillary, the supra- and infraclavicular and the in-
ternal mammary region. Regular follow-up exams are
dependent on institutional preferences and include phys-
ical examination, mammography and sonography and, in
unclear breast findings, magnetic resonance tomography
[11, 12]. In newly diagnosed breast cancer, axillary lymph
node evaluation is usually performed preoperatively by
clinical examination, sonography and lymph node resec-
tion. However, core needle biopsy and ultrasound-guided
fine-needle aspiration cytology (FNAC) [13, 14] have be-
come possible alternatives. In newly diagnosed breast can-
cer, it has already been shown that FNAC can achieve
high accuracy, sensitivity and specificity [11, 15–20] to
predict lymph node metastases. To the authors’ know-
ledge, there are no prospective studies about lymph node
sonography and FNAC in follow-up exams of breast can-
cer patients.
The aim of our study was to evaluate the diagnostic
performance of fine-needle aspiration cytology of sono-




This single-centre investigation was approved by the in-
stitutional review board of the University Hospital Er-
langen and all procedures were in accordance with the
Helsinki Declaration. The need for informed consent
was waived.
Patients
From April 2010 to November 2012, we performed more
than 2500 follow-up exams in patients with breast cancer.
Routine follow-up of patients included clinical examination
and sonography of the breasts and the locoregional lymph
node stations every 6 months for the first 3 years after sur-
gery and then in yearly intervals. Mammography of the af-
fected side was performed every 6 months for the first
3 years after surgery and then yearly; the non-affected
breast was examined by mammography yearly. Patients
who presented with sonomorphologically suspicious lymph
nodes in the ipsi- or contralateral axillary or supra/infracla-
vicular region were eligible to receive FNAC. Prior to
ultrasound-guided FNAC, written informed consent was
obtained from each patient. During this time frame we per-
formed ultrasound-guided FNAC in 59 sonographically
suspicious lymph nodes of 58 patients. Of these, 38 FNAC
probes from 37 patients were obtained from breast cancer
follow-up patients and enrolled for further investigation.
The remaining 21 suspicious lymph nodes of 21 patients
were examined for non-breast cancer follow-up reasons
and therefore not included in this study. Patients with posi-
tive cytology received recurrent stage adapted treatment.
All patients with negative FNAC results were to follow up
by sonography of the locoregional lymph nodes stations
with special focus on the initially punctured lymph
node within three months after the FNAC. If this evalu-
ation revealed no change and no further suspicious
findings, these patients should return to their regular
follow-up examinations.
Sonography
Sonography was performed by a diagnostic breast spe-
cialist (E.W.) with 10 years of experience or by super-
vised residents experienced in breast diagnostic rotation
with high-resolution sonography equipment (15 MHz,
electronic focus, linear-array transducer) (Siemens Acu-
son, Erlangen, Germany). A lymph node was defined as
sonographically suspicious if one of the following char-
acteristics was positive: size (longitudinal > 2 cm; trans-
verse > 1.5 cm); shape (longitudinal/transversal ratio < 2,
round), loss of central fatty hilum, cortex (eccentric or
thickened; > 3 mm, as adopted by Oz et al. [17]) (Fig. 1).
Additionally, all sonographically suspicious lymph nodes
were measured in two planes. If one patient presented
with more than one pathological lymph node in the
same lymph drainage region, the most suspicious lymph
node was selected for FNAC. If the suspicious nodes
were in different topographical regions, one suspicious
node in every region could receive FNAC.
Fine-needle aspiration cytology (FNAC)
All ultrasound-guided FNAC were performed by one
breast specialist (E.W.). After sterile draping and sufficient
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disinfection, a 22-gauge needle attached to a 10-ml syringe
was inserted into and withdrawn from the lymph node
three times under aspiration while sonographically moni-
tored. For suspiciously enlarged or shaped lymph nodes,
the needle was directed into multiple areas of the cortex
and/or hilum. For irregularly shaped lymph nodes, the nee-
dle was directed into the thickest or focally thickened area
of the cortex and/or hilum (Fig. 1). Succeeding FNAC, the
probe was sent to cytology. Following FNAC, patients were
evaluated clinically for 60 min and 1 week after the proced-
ure. Complications (bleeding, hematoma, infection, loss/in-
creased sensation) were also documented.
Cytological evaluation
An expert in cytology and breast pathology [D.W.] with
9 years of experience processed and evaluated all FNAC
material. In order to be able to perform immunocytochem-
ical examinations in equivocal cases, we used cytocentrifu-
gation and the cytoblock technique [21]. The FNAC
cytology sample was concentrated by centrifugation (600 g
for 10 min). The supernatant was removed, and the pellet
was resuspended in PreservCyt Solution (Cytyc Corpor-
ation, Marlborough, MA, USA). After sitting for 15 min,
the sample was run on a ThinPrep 2000 Processor (Cytyc
Corporation, Marlborough, MassachusettsMA, USA). The
resulting slide was stained with Papanicolaou stain, covered
with a coverslip, and evaluated. For the cytoblock tech-
nique, part of the supernatant was fixed in 4 % formalde-
hyde overnight. The next day the specimen was mixed
with Histogel (Thermo Scientific, Waltham, MA, USA)
and was allowed to harden. Subsequently the cytoblock
was cut in 3 μm slices and the slides were stained in
Hematoxylin/Eosin. Specimens were interpreted as follows:
insufficient, no cellular material other than blood; negative,
only normal cellular components present or a specific be-
nign diagnosis; suspicious or malignant, atypical cells sus-
picious or definite for malignancy present (Fig. 2).
Statistical analysis
Statistical analysis was performed using SPSS software
version 21 (IBM, Armonk, New York, USA). Sensitivity,
specificity, negative- (NPV) and positive-predictive
value (PPV) were evaluated for physical examination,
for the different sonomorphological malignancy criteria
and for FNAC.
Fig. 1 Examples of sonographically suspicious axillary lymph nodes that received further fine needle aspiration cytology and cytological evaluation.
a Lymph node presenting a normal size, a longitudinal/transversal ratio < 2, a focal thickening of the cortex (8 mm) and an eccentric hilum.
b Ultrasound-guided fine-needle aspiration cytology. c Lymph node with a round shape (longitudinal/transversal ratio < 2), an indeterminate
size and loss of fatty hilum. d Ultrasound-guided fine-needle aspiration cytology
Fig. 2 Cell block cytology of an investigated lymph node displaying
poorly differentiated breast cancer cells (arrow). The arrowhead indicates
a lymphocyte
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Results
Study population
From April 2010 to November 2012, a total of 57 women
and 1 man underwent ultrasound-guided fine-needle aspir-
ation cytology of 59 axillary or supra- and infraclavicular
lymph nodes. A total of 21 women with 21 cytologically
evaluated lymph nodes were excluded because they were
not breast cancer follow-up patients. Those women re-
ceived FNAC for other reasons, like primary staging of
breast cancer (n = 9), staging of other malignancies (n = 5)
or primarily unknown reasons for lymph node enlarge-
ment (n = 7; mastitis, infection). Therefore, FNAC was per-
formed on 38 lymph nodes in 37 follow-up patients for
breast cancer. The 37 patients consisted of 36 women and
one man with a mean age of 57.0 ± 12.8 years. A total of 19
FNAC were taken in the ipsilateral axilla, 14 in the contra-
lateral axilla, 2 in the ipsilateral supraclavicular region, 1 in
the contralateral supraclavicular region, 2 in the ipsilateral
infraclavicular region and none in the contralateral infra-
clavicular region (Table 1). Follow-up time from primary
diagnosis of breast cancer to the diagnosis of a sonomor-
phologically suspicious lymph node ranged from one
month to 26 years and 6 months (Table 1).
Physical examination
A total of 13/38 sonographically suspicious lymph nodes
were additionally identified by palpation, of which 7 were
located in the ipsilateral axilla, 5 in the contralateral axilla
and 1 in the contralateral supraclavicular. A total of 11 of
these 13 lymph nodes demonstrated a malignant cytology
in FNAC. A total of 10 metastatic lymph nodes were not
suspicious upon palpation, of which 6 were located in the
ipsilateral and 4 in the contralateral axilla. This corre-
sponds to a sensitivity of 52.4 % regarding palpation, a
specificity of 88.2 %, a positive predictive value (PPV) of
84.6 % and a negative predictive value (NPV) of 60 %.
Sonography
Sonomorphological characteristics of the lymph nodes,
which were further assessed with fine-needle aspiration
cytology, are shown in Table 2. All 59 lymph nodes
showed at least one sonomophological pathological fea-
ture. The diagnostic performance of each individual sono-
morphological malignancy criterion for lymph node
evaluation is depicted in Table 3. The sensitivity and the
specificity of the different malignancy criteria ranged from
19–71 % and from 29–88 %, the PPV from 42–75 % and
the NPV from 39–57 %.
Fine-needle aspiration cytology and clinical consequences
FNAC evaluation revealed metastases in 21 lymph nodes
in 21 patients, 20 women and 1 man. A total of 16 pa-
tients with positive FNAC received surgical resection of
the suspicious lymph nodes. Specimen pathology con-
firmed malignancy in all of these cases. A total of 5 pa-
tients with positive cytology did not undergo surgery,
and were instead treated with chemotherapy, antihormo-
nal therapy and/or radiation therapy.
Probe material gathered by fine-needle aspiration was
non-evaluable during cytology in 2 lymph nodes (5.3 %)
of two different patients because insufficient cell mater-
ial was obtained. One was located in the ipsilateral and
one in the contralateral axilla. Both patients with non-
diagnostic cytological findings received successive lymph
node resection of the initially biopsied lymph nodes.
Specimen pathology did not reveal malignancy in either
lymph node. FNAC did not indicate malignancy in 15
lymph nodes from 14 patients (Table 1).
The follow-up group consisted of 16 patients with 17
evaluated lymph nodes including the ones with negative
cytology and the 2 patients with benign results after resec-
tion. To date, none of these patients presented with lymph
node recurrence in the cytologically evaluated sites. The
follow-up time of the patients with negative cytology or
Table 1 Lymph node and patient characteristics dependent on the fine-needle aspiration cytology result
Malignant Benign Non-evaluable
Lymph nodes (n = 38 in 37 patients) 21 15 2
Mean age in years (range) 57 (38 – 72) 56 (30 – 82) 65 (65 – 65)
Lymph node palpable in clinical exam 11 2 0
Mean interval from primary diagnosis to ultrasound-guided
fine-needle aspiration cytology (range)
4y9m (1 m - 13y7m) 7y5m (5 m - 26y6m) 4y6m (2y3m - 6y9m)
Lymph node localisation
• axillar ipsilateral 12 6 1
• axillar contralateral 7 6 1
• supraclavicular ipsilateral 1 1 0
• supraclavicular contralateral 1 0 0
• infraclavicular ipsilateral 0 2 0
• infraclavicular contralateral 0 0 0
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histology ranged from 22 months (1 year 10 months) to
53 months (4 years 5 months). Thus, FNAC demonstrated
sensitivity and specificity of 100 % of sonomorphologically
suspicious lymph nodes excluding the two cytologically
non-evaluable probes.
Fine-needle aspiration cytology side-effects
None of our patients demonstrated acute or delayed side
effects from FNAC (bleeding, hematoma, infection, loss/
increased sensation).
Discussion
Follow-up exams in breast cancer patients have to man-
age a fine line between early detection of recurrence and
overdiagnosis. Follow-up concepts include clinical exam-
ination and mammography [11, 22, 23]. Lymph node
sonography is performed in most institutions only if
lymph node stations are suspicious on palpation or more
uncommonly on each follow-up appointment [11, 12,
23, 24]. MRI is usually recommended if the differenti-
ation between scar and recurrent disease is necessary or
in women at high risk for breast cancer [25]. If there is
an unclear lymph node finding on clinical or imaging
examination, the woman has the choice between inva-
sive diagnostic procedures like core needle biopsy or
lymph node dissection. On the other hand, the woman
could choose short follow-up exams especially in unclear
lymph node findings. This might induce unnecessary
anxiety in the patient up to the next control date.
The minimally invasive procedures core needle biopsy
[13, 26, 27] and FNAC have already been successfully tested
in lymph nodes of newly diagnosed breast cancer [13, 14,
20, 28–31]. For core needle biopsies, a technique adapted
to the axillary anatomy is recommended to minimize side
effects [26]. A meta-analysis of data from 21 studies and
4313 patients showed that the pre-operative ultrasound of
Table 2 Sonomorphological characteristics of the lymph nodes which were further assessed with fine-needle aspiration cytology
Metastasis (n = 21) No metastasis (n = 15) Non-evaluable cytological probe (n = 2)
Lymph node size longitudinal
> 2.0 cm 15 8 1
< 2.0 cm 6 7 1
Lymph node size transversal
> 1.5 cm 6 2 0
< 1.5 cm 15 13 2
Lymph node shape (longitudinal/transversal ratio)
- round (<2) 14 13 0
- oval (>2) 7 2 2
Hilum
- loss of fat 16 10 2
- eccentric 4 2 0
Thickened cortex 5 6 1
Table 3 Diagnostic performance of physical examination, different sonomorphological malignancy criteria and fine-needle aspiration
cytology for lymph node evaluation in breast cancer follow-up
Sensitivity Specificity Positive predictive value Negative predictive value
Physical examination 52.4 % 88.2 % 84.6 % 60 %
Sonomorphological malignancy criteria
Lymph node enlargement:
- longitudinal > 2.0 cm 71.4 % 47.1 % 62.5 % 57.1 %
- transversal > 1.5 cm 28.6 % 88.2 % 75 % 50 %
Round shape (longitudinal/transversal ratio <2) 66.7 % 23.5 % 51.8 % 36.4 %
Loss of fatty hilum 76.2 % 29.4 % 57.1 % 50 %
Eccentric hilum 19 % 88.2 % 66.7 % 46.9 %
Thickened cortex 23.8 % 58.8 % 41.7 % 38.5 %
Fine-needle aspiration cytologya 100 % 100 % 100 % 100 %
aexcluding the two non-evaluable cytological probes
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axillary lymph nodes in primary breast cancer resulted in a
median sensitivity of 61.4 % (interquartile range 51.2–
79.4 %) and a median specificity of 82 % (interquartile range
76.9–89 %) [32]. In a subset of 1733 patients in the same
meta-analysis, the median sensitivity of ultrasound needle
biopsy (results for core biopsy and FNAC) was 79.4 %
(interquartile range 68.3–88.9 %) and the median specificity
was 100 % (interquartile range 100–100 %) [32]. No explicit
difference was found in this meta-analysis whether FNAC
or core biopsies were performed. In a meta-analysis of 20
studies with 1371 subjects, the performance of FNAC for
lymph node metastases in primary breast cancers resulted
in a pooled sensitivity of 66 % (95 % CI was 64–69 %) and a
specificity of 98 % (95 % CI was 98–99 %) [14]. As pre-
sented the diagnostic performance, especially the sensitivity
of FNAC in post-operative breast cancer follow-up is much
higher than in the preoperative staging of breast cancer pa-
tients. We believe that this is due to the different workflows
and evaluation processes. In preoperative staging FNAC
has been performed even if no lymph node was sonomor-
phologically suspicious on a random lymph node, in order
to rule out metastases. However, if micrometastases had
been present and coincidentally FNAC had been performed
on a lymph node from a different draining system, these
metastases could have not been detected by FNAC. The by
us presented workflow eliminates the uncertainty of which
lymph node to pick for FNAC, as the probed lymph node
had to be newly detected and suspicious (either by physical
examination or sonography), possibly explaining the perfect
sensitivity. The excellent specificity of FNAC is in accord-
ance to previous work [14], especially when performed by
an experienced cytologist.
As in the pre-surgical studies, we show that FNAC is
also reliable in lymph node stations that have already been
tested. FNAC demonstrated sensitivity and specificity of
100 % during the assessment of sonomorphologically sus-
picious lymph nodes when excluding two cytologically
non-evaluable probes. Regarding cost-effectiveness, FNAC
is proposed to be routinely included in pre-operative
evaluation of lymph nodes [10, 13, 32, 33]. With the intro-
duction of FNAC in suspicious lymph nodes in women
who were examined during follow-up, we wanted to offer
the least invasive tissue sampling method with a justifiable
cost-benefit ratio. Furthermore, FNAC could be easily im-
plemented in our follow-up procedure on the same day of
the follow-up exam without major side effects. This is
in accordance with various studies investigating FNAC
in the primary diagnosis and staging of breast cancer
[10, 16–18, 20].
A total of 2 of 38 performed FNAC probe material gath-
ered by fine-needle aspiration were non-evaluable during
cytology because insufficient cell material was obtained.
Both lymph nodes were completely resected and did not
reveal metastatic infiltration in specimen pathology. All 15
patients demonstrating a negative FNAC were followed
up clinically. Post-interventional examinations were per-
formed one week (physical examination) and 3 months
(physical examination, ultrasonography) after FNAC in
addition to the routine follow-up protocol. During our
surveillance period over 22–53 months, none of the 15
patients developed lymph node recurrence in the lymph
region in which FNAC was performed. In our study, no
complications were observed in any of the patients who
underwent FNAC, which again demonstrates the safety of
FNAC [15–18, 26, 33].
Clinical examination of lymph nodes in newly diag-
nosed breast cancer is already difficult because large
reactive lymph nodes can be misleading and small
metastatic lymph nodes are not palpable [14]. Treated
lymph node stations are even more difficult to examine
because of possible post-treatment side effects like scar-
ring or hematoma. This follows from our evaluation, as
clinical examination was suspicious only in 11/21 ma-
lignant lymph nodes.
Though routine clinical examination is highly rec-
ommended in all follow-up programs, it is still unclear
whether it contributes to relevant early recurrence de-
tection. In a meta-analysis, there was no evidence that
clinical examination contributes to survival advantage,
as the majority of in-breast relapses are detected by
patients or by mammography [34]. The rare axillary
relapse is more often detected by clinical examination,
as the axillary region is insufficiently evaluable on
mammography and sonography was not performed in
these studies.
Regarding sonography, all lymph nodes that were in-
cluded in the study had at least one suspicious feature
and only 21/37 lymph nodes were malignant. If evalu-
ated separately, the different sonomorphological malig-
nancy criteria reached a sensitivity and specificity ranging
from 19–71 % and from 29–88 %.
Limitations of the study are the small number of pa-
tients and the single institutional execution, however the
initial experiences are promising.
Another limitation of the study is that the FNAC-
negative lymph nodes were not histologically verified
and were only followed up. A follow-up time of at least
22 months seemed to be appropriate to define those
lymph nodes as stable and consequently negative.
Sonography of lymph nodes after breast cancer treatment
can be challenging. The sonographer has to differentiate
between postsurgical alteration and chronic inflammation
due to lymph edema or recurrent disease in the lymph
nodes. The small number of patients seemed inadequate
for the synthesis of further conclusions as to the value of
the different ultrasound criteria.
We did not investigate the role of color Doppler ultra-
sound findings, which were described to be helpful in the
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differentiation of benign and malignant lymph nodes in
primary breast cancer. Several studies have evaluated the
vascularity of benign and malignant axillary lymph nodes,
but the results were not consistent across the different
studies, especially for lymph nodes smaller than 1 cm
[35–37]. Recently, elastography was introduced as an
additional feature in sonography of breast disease. In a
prospective study of 104 axillary lymph nodes, strain
elastography showed no improvement in diagnostic ac-
curacy [38].
To date, it remains unclear which follow-up strategy
is best for women to detect early recurrent disease and
to minimize anxiety due to medical appointments. De-
bate persists with respect to the timeframe, extent of
clinical and imaging examinations. Yearly mammog-
raphy and clinical examination are the minimum guide-
line recommendations [11, 12, 22, 39]. Individual risk
adapted follow-up examinations in future guidelines de-
signed for optimal disease management are proposed
[39, 40]. Based on the results of this study, we can recom-
mend FNAC as an additional diagnostic step regardless of
the modality of a suspicious lymph node diagnosed during
follow-up exams.
Conclusions
FNAC is a safe and reliable diagnostic tool for the evalu-
ation of suspicious lymph nodes in breast cancer follow-
up. It distinctly improves diagnostic performance of the
evaluation of suspicious lymph nodes compared to clin-
ical examination and an analysis based on sonomorpho-
logical malignancy criteria alone.
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